About the study
The Molecular Screening and Therapeutics (MoST) Program is a clinical research program that is testing a new approach to providing treatments for patients with cancer. MoST-LLy is a cohort within MoST that is just for patients with blood cancers. The MoST program personalises experimental treatment based on an individual’s unique cancer genetic profile, rather than where their cancer originates.
If a patient is suitable for the program, their blood cancer is tested to see if the DNA contains genetic biomarkers that can guide treatment. This process is called molecular screening or genetic testing. After a patient’s blood cancer is tested, a report is sent to their referring haematologist with information on (i) any genetic biomarkers that were identified and (ii) the types of treatment that may be suitable.
QIMR Berghofer is now a national remote consenting hub for the MoST-LLy study extending access for patients to all parts of Australia.
For further information about this program see also Understanding the Blood Cancer Genomics Trial: Leukaemia Foundation (Australia).
The MoST-LLy research program is a collaboration between QIMR Berghofer, led by Professor Steven Lane, Group leader of The Gordon and Jessie Gilmour Leukaemia Research Laboratory at QIMR Berghofer and clinical haematologist at Royal Brisbane and Women’s Hospital, the Garvan Institute of Medical Research, SA Pathology, PathWest, Omico (the Australian Genomic Cancer Medicine Centre) and the NHMRC Clinical Trials Centre at the University of Sydney. This program has ethics approval from St Vincent’s Hospital Human Research Ethics Committee (2019/ETH03114) and the University of Sydney is the regulatory sponsor of clinical trials undertaken through the program. MoST-LLy has generously been co-funded by The Leukemia Foundation, Tour de Cure and the Medical Research Future Fund (MRFF).
Further information can be found following external links:
Participation
- patients with advanced or poor-prognosis blood cancer of any type
- patients aged 18 years and over
- patients with limited treatment options, or who are receiving their last line of standard therapy.